Navigation Links
ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
Date:9/15/2010

EXTON, Pa., Sept. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI), a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.  VP20621 contains the spores of a naturally occurring non-toxin producing strain of C. difficile.  

The poster entitled 'Phase 1 Evaluation of an Oral Suspension of VP 20621, Spores of a Non-Toxigenic C. difficile Strain (NTCD), in Healthy Older Subjects Pretreated With Oral Vancomycin' is being presented today at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in poster session F1-2127b by Stephen Villano, M.D., ViroPharma's vice president of clinical research and development.

The Phase 1 study was designed to determine the safety and tolerability of VP20621 dosed orally as single and repeat escalating doses in healthy young (18 to 45 years of age) and older (60 years of age and older) adults.  Because VP20621 was shown to be well tolerated following single and repeat doses in younger and older healthy subjects, the company also performed repeat dosing in older adults following exposure to oral antibiotic.  The new data presented today was from healthy subjects above 60 years of age who were pre-dosed with oral vancomycin to disrupt their gastrointestinal flora and render them potentially susceptible to C. difficile colonization. Subjects were subsequently given either placebo or VP20621 doses of 10(4),10(6), or 10(8) spores (once daily for 14 days).  Conclusions from the study include:

  • Multiple doses of VP20621 were ge
    '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... GLEN BURNIE, Md. , Feb. 26, 2015 ... patient recruitment solutions for the clinical research industry, ... Karen Welch as a Project Manager, ... Team. Photo - http://photos.prnewswire.com/prnh/20150225/177750 ... Project Manager with a demonstrated ability to successfully ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015 ... sector, giving birth to effective, inexpensive and ... encouraged researchers to build small-scale, potent devices, ... Logo - http://photos.prnewswire.com/prnh/20150225/177944LOGO ... & Sullivan, Innovations in Nanomanufacturing, finds that ...
(Date:2/26/2015)... , Feb. 26, 2015   Coverall North ... franchised businesses, today celebrates 30 Years of Clean, a ... anniversary. Coverall started in 1985 as a ... and is now a leading global brand ... Coverall,s passion and mission have remained consistent: To promote ...
Breaking Medicine Technology:CSSi's Continued Growth Brings Talented New Hire - Karen Welch Welcomed as Project Manager 2Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 2Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 3Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 4Coverall Celebrates 30 Years of Clean 2Coverall Celebrates 30 Years of Clean 3
(Date:2/26/2015)... Catalent Pharma Solutions, the ... and development solutions for drugs, biologics and ... expanded capabilities within its European Clinical Supply ... in response to increased customer demand for ... highly-potent or temperature-sensitive investigational medical products continues ...
(Date:2/26/2015)... February 26, 2015 A Beautiful Smile ... practice is offering the following 50 year celebration specials ... their choice of Sonic Care Diamond Clean or the ... respectively). The cost is $2895 for the Invisalign ... more than ten treatment procedures are priced accordingly). ...
(Date:2/26/2015)... 26, 2015 Software and Cybersecurity ... Position and Best Practices for Compliance, **Presented by ... MD, http://www.fdanews.com/SoftwareAndCybersecurity , This workshop — ... has been specifically designed to provide attendees with ... assure medical device software safety. , In fact, ...
(Date:2/26/2015)... Linda, CA (PRWEB) February 26, 2015 ... , “Diversity of extracellular vesicles and their cargo in ... extracellular vesicles and their relevance for cell-to-cell communication. The ... live March 4, 2015 at 8:00am PT. , Every ... extracellular vesicles (EVs) , often called “exosomes” or ...
(Date:2/26/2015)... Kantar Health UK, a leading global healthcare consulting ... Companies to Work For” list for 2015. This was the ... list, which measures employees’ levels of fulfilment, motivation and engagement. ... UK, and we are delighted to be included in this ... said. “The team is dedicated to putting clients first. We ...
Breaking Medicine News(10 mins):Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 2Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 3Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 2Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 3Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 2Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 3Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 4Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Kantar Health UK Named One of The Sunday Times 100 Best Small Companies to Work For 2
... Jan. 7 Insulet Corporation (Nasdaq: PODD ... OmniPod(R) Insulin Management System, today announced the company will ... Management is scheduled to present an overview of the ... at The Westin St. Francis in San Francisco, CA.During ...
... Beneficiaries Introduced on the First Day of 111th ... Physical therapy services for Medicare beneficiaries would ... under legislation introduced Tuesday in the Senate and ... Therapy Association (APTA). The Medicare Access to Rehabilitation ...
... a statement by Lois Aronstein, AARP NY State Director:Governor ... recommendations on a number of issues that are essential ... Yorkers of all ages.AARP commends the Governor for proposing ... percent of the federal poverty level, making more than ...
... have identified mutations in a gene that predict a ... leukemia (ALL). Although the researchers caution that further research ... called IKZF1 or IKAROS, lead to leukemia relapse, the ... diagnostic tests to assess the risk of treatment failure. ...
... SYK ) announced today that it will participate in the following ... January 14, 2009 -- 10:00 a.m. Pacific Time, ... San Francisco, ... will be available on,Stryker,s website at www.stryker.com via the For Investors ...
... WESTCHESTER, Ill., Jan. 7 BrainLAB, Inc., ... medical treatments,announces a new, customer-focused sales and ... growth and an expanding product,portfolio. , ... and support structures, customers will benefit,from a ...
Cached Medicine News:Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 3Health News:Gene abnormality found to predict childhood leukemia relapse 2Health News:Gene abnormality found to predict childhood leukemia relapse 3Health News:Gene abnormality found to predict childhood leukemia relapse 4Health News:Stryker To Present at Investor Conference 2Health News:BrainLAB, Inc. Announces New, Streamlined Surgery Business Division 2
... first wavefront aberrometer specifically designed to meet ... Practitioner. Utilizing a proprietary, non Hartmann-Shack technology ... accurately measures high order aberrations (3rd-6th order), ... to arrive at a fully optimized prescription ...
... Heidelberg Multi Color (HMC) ... a microprocessor-controlled precision assessment ... the red/green range (Rayleigh ... (Moreland equation) with integrated ...
... Alcons new Infiniti Vision System is ... surgical instrument. This single instrument now ... methods to remove a cataract. The ... and unique tri-modal energy delivery options ...
... MDoffice seamlessly integrates practice management ... and simplify office and clinical ... charting, billing, accounting and reporting ... facilities and specialties. MDoffice immediately ...
Medicine Products: